Stocktoria
Foghorn Therapeutics Inc. FHTX
Foghorn Therapeutics Inc. (FHTX) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $30.9M at a -240.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.522 |
| Retained earnings / assets | -3.193 |
| EBIT / assets | -0.436 |
| Equity / liabilities | -0.354 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| FHTX | Foghorn Therapeutics Inc. | 1/9 | -10.28 | — | +36.8% |
| VSTM | Verastem, Inc. | 4/9 | -15.71 | — | +209.1% |
| ZOMDF | Zomedica Corp. | 3/9 | 1.07 | — | +17.4% |
| CUE | Cue Biopharma, Inc. | 4/9 | — | — | — |
| CELU | Celularity Inc | 1/9 | — | — | -51% |
| VRCA | Verrica Pharmaceuticals Inc. | 5/9 | -19.42 | — | — |
| ETST | Earth Science Tech, Inc. | 4/9 | — | 12.7 | +7.8% |
About Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
FAQ
Is FHTX financially healthy?
Foghorn Therapeutics Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does FHTX pay a dividend?
No, Foghorn Therapeutics Inc. does not currently pay a dividend.
How profitable is FHTX?
In FY2025, Foghorn Therapeutics Inc. had a net margin of -240.3%.
What is the analyst price target for FHTX?
The average Wall-Street price target for Foghorn Therapeutics Inc. is $11.44, about 72.4% above the recent price, from 9 analysts.
Is FHTX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Foghorn Therapeutics Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.